Quoin Pharmaceuticals rises on FDA clearance to enroll teenage patients in ongoing studies

Quoin Pharmaceuticals

04/03/2024 18:21

** Israel-based drug developer Quoin Pharmaceuticals'
 QNRX.O   2EBy.BE  shares rise 26.7% to $3.51  
    ** Co announces U.S. FDA clearance to recruit subjects aged
14 years and older for two ongoing studies testing its
experimental treatment for a rare inherited disorder 
    ** FDA clearance represents the very first time that
non-adult patients with Netherton syndrome will be tested in
open label clinical studies - QNRX
     ** Netherton syndrome is a rare hereditary skin disorder
that leads to severe skin barrier defects and excessive skin
shedding
    ** The treatment, QRX003, is a topical lotion that helps
reduce the skin-shedding process 
    ** Including session moves, stock has fallen 47.9% in the
last 12 months 

 (Reporting by Sneha S K in Bengaluru)
 ((Sneha.SK@thomsonreuters.com;))